The European Medicines Agency (EMA) announced on Wednesday June 15 the launch of the review process for a modified version of Pfizer's Covid-19 vaccine to better protect against specific variants of the virus, including Omicron .
To discover
LIVE - Legislative 2022: follow the negotiations the day after the first round
Read also“
Covid: the race against time for the CEO of Pfizer
”
“
As the company progresses with the development of its suitable vaccine, the EMA will receive more data, including data on the immune response to the vaccine, as well as data on its effectiveness against the subvariants of Omicron
”, underlines the EMA in a press release.
